BioSpace News Archive

RemeGen Co., Ltd., a commercial-stage biotechnology company, recently released data from the Phase II clinical study of its proprietary novel fusion protein Telitacicept for the treatment of myasthenia gravis in Chinese patients, showing positive results.

Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced it will report its third quarter financial results and provide an update on the cytisinicline development program on Monday, November 14, 2022, at 4:30 PM EST.

Intrinsic Medicine, Inc. (Intrinsic), a therapeutics company leveraging human milk biology to transform Gut-Brain Axis (GBA) and inflammatory disorders, and Phoenix Biotech Acquisition Corp. (NASDAQ:PBAX) (PBAX), a special purpose acquisition company formed for the purpose of acquiring or merging with one or more businesses, today announced they have entered into a definitive business combination agreement.

Biomea Fusion, Inc. today announced the dosing of the first patient with type 2 diabetes in the Phase II portion of COVALENT-111, a Phase I/II clinical trial underway in Canada.

Pluri Inc. today announced its participation in three upcoming conferences. Conference: CPHI Frankfurt Date: November 1-3, 2022 Location: Frankfurt, Germany.

Compugen Ltd. announced today that the Company will release its third quarter 2022 financial results on Monday, November 14, 2022, before the U.S. financial markets open.

CytoSorbents Corporation announced today that the National Institute of General Medical Sciences (NIGMS), a division of the U.S. National Institutes of Health, has granted CytoSorbents a Phase I Small Business Innovation Research (SBIR) award valued at $281,835.

ESSA Pharma Inc. today announced that Janssen Research and Development (“Janssen”) is suspending enrollment into the Phase 1 clinical study of EPI-7386 with apalutamide or EPI-7386 with abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer (“mCRPC”) patients as a result of operational recruitment challenges.

EpiVax, Inc. (“EpiVax”) is pleased to announce participation in a new project with Intravacc, funded by CEPI (Coalition for Epidemic Preparedness Innovations), to develop universal vaccines for betacoronaviruses, including SARS-CoV-2.

Antengene Corporation Limited (“Antengene” SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hematology and oncology, today announced that the Investigational New Drug (IND) application for ATG-017 has received clearance from the U.S. Food and Drug Administration (FDA).